Journey Medical Q2 revenue up 23% to $18.5M; net loss narrows to $0.3M

Journey Medical Corp

Total revenues $18.5M for Q2 2026, +23% from $15.0M in Q2 2025; Emrosi sales $8.1M.
GAAP net loss narrowed to $0.3M ($0.01/sh) from $3.8M ($0.16/sh) year ago.
Non-GAAP EBITDA and Adjusted EBITDA positive for both three and six months ended June 30, 2026.
Cash $25.6M at June 30, 2026 vs $24.1M at Dec 31, 2025; SG&A down $1.0M to $10.9M.
Emrosi total prescriptions ~36,000 in Q2 2026, up from ~30,000 in Q1 and ~27,000 in Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.